↓ Skip to main content

DOACs – advances and limitations in real world

Overview of attention for article published in Thrombosis Journal, October 2016
Altmetric Badge

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
163 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
DOACs – advances and limitations in real world
Published in
Thrombosis Journal, October 2016
DOI 10.1186/s12959-016-0111-3
Pubmed ID
Authors

Lai Heng Lee

Abstract

The group of new oral anticoagulants or NOACs, now termed direct oral anticoagulants or DOACs, with their favourable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. Dabigatran, rivaroxaban, apixaban and edoxaban are now in clinical routine use for prevention and treatment of arterial and venous thrombotic diseases as addressed in their clinical trials. Usage of the DOACs is expected to increase as clinicians gain more experience and reassurance with data from the real world studies which are generally consistent with that from clinical trials. Development of specific antidotes in management of bleeding complications and development of coagulation assays for their plasma levels will further boost the confidence in the DOACs. Nonetheless, there are still limitations associated with the DOACs. Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible for treatment with a DOAC. Conditions where more data is required include DOACs use in the paediatric age group, patients with atrial fibrillation and valvular heart disease, thrombosis associated with the anti-phospholipid syndrome and cancer associated thrombosis. The affordability and access to these drugs may pose an issue for many patients under healthcare systems not providing for these medications. With four new anticoagulants coming onboard very quickly, the focus has shifted to the practical approach and management in real life as many clinicians are not yet familiar with the DOACs. Clinicians need to be educated on how to manage this new class for drugs, from choosing the appropriate drug to prevention and managing bleeding complications as a lack of knowledge and understanding in these drugs will lead to inappropriate use and compromise on patient safety.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Greece 1 <1%
Denmark 1 <1%
Slovenia 1 <1%
Unknown 160 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 34 21%
Researcher 16 10%
Student > Postgraduate 16 10%
Student > Bachelor 16 10%
Student > Ph. D. Student 13 8%
Other 28 17%
Unknown 40 25%
Readers by discipline Count As %
Medicine and Dentistry 52 32%
Pharmacology, Toxicology and Pharmaceutical Science 29 18%
Agricultural and Biological Sciences 6 4%
Biochemistry, Genetics and Molecular Biology 6 4%
Chemistry 5 3%
Other 12 7%
Unknown 53 33%